Investment Rating - The report gives an "Accumulate" rating for the company based on the continuous increase in innovative drug revenue and the acceleration of multiple key new drugs in clinical trials [2][5][17]. Core Insights - The company is a leading player in the domestic chronic disease management sector, focusing on comprehensive treatment solutions in the cardiovascular, renal, and metabolic fields. It has six approved innovative drugs, with over 50% of its revenue coming from innovative drugs, and 85 new drugs in the pipeline [1][5]. - The company is advancing its research on new targets and has a strong focus on managing the entire lifecycle of cardiovascular diseases, particularly hypertension and heart failure. The core commercial pipeline is expanding, with significant clinical trials underway [1][2][5]. - The company is also diversifying into metabolic and oncology fields, developing various drug types to address different clinical needs, including small molecules, monoclonal antibodies, and gene editing therapies [2][5]. Summary by Sections 1. Company Overview - The company has been deeply involved in chronic disease treatment for nearly 30 years, establishing itself as a leader in the field. It has a comprehensive product matrix that includes cardiovascular drugs, antibiotics, and orthopedic medications, with a focus on high-end interventional medical devices [24][25]. - The company has accelerated its innovation transformation since 2012, with a significant increase in its innovative drug pipeline, including the introduction of new drugs with global intellectual property rights [25][29]. 2. Focus on Cardiovascular Treatment - The company is addressing the high prevalence of cardiovascular and metabolic diseases, which often coexist, by developing a multi-target and multi-mechanism drug pipeline. This includes a range of drug types aimed at providing comprehensive management solutions for patients [51][56]. - The report highlights the need for new mechanisms and long-acting/oral formulations in the treatment of cardiovascular and metabolic diseases, given the current low treatment and control rates in China compared to developed countries [52][56]. 3. Financial Projections - The company is expected to achieve revenues of 44.29 billion, 53.58 billion, and 64.15 billion yuan from 2025 to 2027, with year-on-year growth rates of 10.4%, 21.0%, and 19.7% respectively. The net profit attributable to the parent company is projected to be 6.59 billion, 7.97 billion, and 9.49 billion yuan during the same period [2][17]. - The report indicates that the revenue structure is improving, with a significant increase in the proportion of innovative drug revenue, which is expected to enhance the company's profitability [35][38].

Group 1: Oil Crisis Historical Review and Investment Insights - The oil crisis typically begins with geopolitical conflicts and escalates due to expectations of supply disruptions, leading to short-term price spikes and long-term price increases [1][12] - The macroeconomic impact of oil crises has historically led to inflation followed by stagnation or similar conditions, with the 1970s crisis resulting in recession and stagflation in the US, while the 2022 situation only saw a technical recession [1][12] - Market narratives have evolved, reflecting learning effects from past crises, with shifts from valuation model failures to asset worship and supply-side reforms [1][12] - Asset performance during crises shows that commodities like oil benefit directly, while equities face valuation pressures, and bonds initially decline before rising due to inflation expectations [1][12] Group 2: Logistics and Transportation Sector - The daily traffic volume at Ganqimaodu Port has shown a steady recovery, with an average of 1,351 vehicles per day from March 16 to March 22, 2026, marking a 55.7% year-on-year increase [5][17] - The port's cargo throughput has also increased significantly, with a 35% year-on-year growth to 10.24 million tons as of March 15, 2026 [5][17] - Short-distance freight rates have stabilized and increased, averaging 65 RMB per ton in 2026, reflecting an 8.3% year-on-year rise [6][17] Group 3: Company-Specific Insights - Jiayou International reported a revenue of 2.486 billion RMB in Q3 2025, a 30.61% year-on-year increase, driven by the recovery of cross-border business and rising prices of coking coal [7][18] - The company is expected to benefit from the integration of mining services, logistics, customs clearance, and coal sales, enhancing its competitive advantage in the cross-border logistics market [7][18] - Northern International is projected to benefit from rising coking coal and European natural gas prices, with a target price of 18 RMB based on a 24x PE ratio for 2026 [31][32] Group 4: Social Services Sector - The social services sector is experiencing a policy-driven boost in consumer spending, particularly in travel and hospitality, with recommendations for various hotel and tourism companies [19][20] - The education sector is also seeing robust demand, with significant expansion opportunities in high school education and vocational training [20][23] - Traditional retail is undergoing transformation, with new consumption patterns emerging and companies adapting to changing market dynamics [20][23]

Investment Rating - The report assigns a rating of "Accumulate" to the company with a target price of 66.68 CNY [6]. Core Insights - The company, Xinlitai, is a leading innovative pharmaceutical enterprise focusing on chronic diseases related to heart and kidney metabolic syndrome (CKM). By February 2026, it is expected to have six Class 1 innovative drugs approved for market, with a significant clinical pipeline, particularly JK07, which shows potential for heart failure treatment [2][12]. - The company ranks first globally in the number of new molecular entity (NME) hypertension drugs approved since 2012 and is recognized for its two key hypertension products, which are expected to drive sales growth [12]. - The potential market for heart failure treatment, particularly for JK07, is estimated to exceed 100 billion USD, indicating substantial commercial potential [12]. Financial Summary - Total revenue is projected to grow from 3,365 million CNY in 2023 to 6,478 million CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 21.4% [4][13]. - Net profit attributable to shareholders is expected to increase from 580 million CNY in 2023 to 1,003 million CNY in 2027, with a CAGR of about 21.4% [4][13]. - Earnings per share (EPS) is forecasted to rise from 0.52 CNY in 2023 to 0.90 CNY in 2027, indicating a steady growth trajectory [4][13]. Market Position - Xinlitai is positioned as a leader in the hypertension treatment sector, with its product "Xinlitai" being the best-selling ARB drug in China as of 2024, and "Xinchao" being the first ARNi drug approved in China and the second globally [12]. - The company has a robust pipeline in lipid metabolism, targeting various key indicators and treatment modalities, which enhances its comprehensive management of dyslipidemia [12].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 66.68 CNY [6]. Core Insights - The company, Xinlitai, is a leading innovative pharmaceutical enterprise focusing on chronic diseases related to heart and kidney metabolic syndrome (CKM). By February 2026, it is expected to have six Class 1 innovative drugs approved for market, with the key clinical pipeline JK07 showing potential for heart failure treatment [2]. - The company ranks first globally in the number of new molecular entity (NME) hypertension drugs approved since 2012 and is recognized for its two pillar hypertension products, which are expected to drive significant sales growth [12]. - The potential market for heart failure treatment, particularly for JK07, is estimated to exceed 100 billion USD, indicating substantial commercial potential [12]. Financial Summary - Total revenue is projected to grow from 3,365 million CNY in 2023 to 6,478 million CNY by 2027, reflecting a compound annual growth rate (CAGR) of approximately 21.4% [4]. - Net profit attributable to shareholders is expected to increase from 580 million CNY in 2023 to 1,003 million CNY in 2027, with a CAGR of about 21.4% [4]. - Earnings per share (EPS) is forecasted to rise from 0.52 CNY in 2023 to 0.90 CNY in 2027, indicating a strong growth trajectory [4]. Market Position - Xinlitai is positioned as a leader in the hypertension treatment sector, with its product "Xinlitai" being the best-selling ARB drug in China as of 2024, and "Xinchao" being the first ARNi drug approved in China and the second globally [12]. - The company has a robust pipeline in lipid metabolism, targeting various key indicators and treatment modalities, which enhances its comprehensive management of dyslipidemia [12].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company is a leader in the domestic cardiovascular and renal metabolic syndrome market, accelerating its innovative transformation with nearly 46% of its revenue coming from innovative drugs in the first three quarters of 2025, up from 27% in 2023 [2][36]. - The hypertension product matrix is rich, with key products like Xinchaotuo expected to contribute nearly 4 billion yuan in peak sales [2]. - The global innovative pipeline has significant potential, particularly with JK07, which is expected to break through the treatment bottleneck for heart failure [3]. Summary by Sections Section 1: Domestic Leader in Cardiovascular and Renal Metabolic Syndrome - The company has been deeply engaged in the cardiovascular field for over 20 years, establishing a comprehensive product matrix that includes cardiovascular, renal, metabolic, and orthopedic innovations [2][24]. - The company has launched six innovative drugs and has a robust pipeline with 85 projects under development, ensuring strong future growth [2][40]. Section 2: Rich Hypertension Product Matrix - The prevalence of hypertension is increasing, with the rate rising to 31.6% among adults from 2020 to 2022, indicating a significant market opportunity [49]. - Xinchaotuo, the second ARNI drug globally, is expected to achieve rapid market penetration after its approval in 2025, with peak sales projected at nearly 4 billion yuan [2][58]. - Other innovative drugs like Xinlitai and Fuliantian are also expected to see stable growth and rapid market entry due to their inclusion in medical insurance [2][53]. Section 3: Significant Potential of JK07 - JK07, targeting heart failure patients, has shown promising results in early clinical trials and is expected to be approved by 2029, potentially generating substantial revenue [3][45]. Section 4: Comprehensive Development in Renal, Metabolic, and Orthopedic Fields - The company is advancing its renal anemia product, Ennaruo, which is expected to accelerate its market presence [3][40]. - The metabolic field is also being addressed with innovative drugs like Xinlitai, which is set to be approved in 2024 and included in primary care guidelines by 2025 [3][40]. Section 5: Profit Forecast and Valuation - The company is projected to achieve revenues of 43.37 billion yuan, 50.36 billion yuan, and 59.91 billion yuan from 2025 to 2027, with corresponding net profits of 6.40 billion yuan, 7.72 billion yuan, and 9.48 billion yuan [4][8].

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is a pioneer in the treatment of cardiovascular-renal-metabolic syndrome in China, ranking as the second-largest pharmaceutical company in the cardiovascular innovative drug sector by revenue in 2024 [3] - The company has a robust pipeline of innovative drugs, with a focus on addressing the unmet medical needs in the cardiovascular-renal-metabolic syndrome area, which is characterized by the pathological interaction between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system [3][10] Product Portfolio - The company leads innovation in the cardiovascular-renal-metabolic syndrome field with six innovative drugs, including Xinlitai (approved in 2013), Fuli-tan (2024), Xinlitin (2024), Xinchao-tuo (2025), Fuli-an (2025), and Ennalro (2023) [4] - The sales revenue from innovative drugs is projected to increase from 30.1% in 2023 to 37.7% in 2024, and further to 51.6% by 2025 [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately CNY 3.365 billion, CNY 4.012 billion, and CNY 3.241 billion respectively [6] - The net profit after tax for the same periods is approximately CNY 580 million, CNY 605 million, and CNY 591 million respectively [7] - The gross profit margin is expected to improve from 68.3% in 2023 to 75.3% in 2025 [8] Industry Overview - Cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolic disorders pose a significant burden on global public health, with the prevalence of cardiovascular-renal-metabolic syndrome reaching 88.9% among adults globally in 2024 [10][12] - The market for treatment drugs for cardiovascular-renal-metabolic syndrome is projected to grow from USD 328.9 billion in 2020 to USD 468.4 billion in 2024, with a compound annual growth rate (CAGR) of 9.2%, expected to reach USD 722.5 billion by 2029 [12]

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is a pioneer in the treatment of cardiovascular-renal-metabolic diseases in China, ranking as the second-largest pharmaceutical company in the cardiovascular innovation drug sector by revenue in 2024 [3] - The company has a robust pipeline of innovative drugs targeting unmet medical needs in the cardiovascular-renal-metabolic syndrome area, which is characterized by the pathological interaction between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system [3][8] Product Portfolio - Xinlitai has six innovative drugs, including Xinlitai (approved in 2013), Fuli Tian (expected approval in 2024), Xinlitin (expected approval in 2024), Xinchao Tuo (expected approval in 2025), Fuli An (expected approval in 2025), and Ennaloro (approved in early 2023 with expanded indications expected in 2025) [4] - The sales revenue from innovative drugs is projected to increase from 30.1% in 2023 to 37.7% in 2024, and further to 51.6% by 2025 [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately CNY 3.365 billion, CNY 4.012 billion, and CNY 3.241 billion, respectively [5] - The net profit after tax for the same periods was approximately CNY 580 million, CNY 605 million, and CNY 591 million [5] - Gross margins improved from 68.3% in 2023 to 75.3% in 2025 [6] Industry Overview - Cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolic disorders represent a significant burden on global public health, with the prevalence of cardiovascular-renal-metabolic syndrome reaching 88.9% among adults globally in 2024 [8][10] - The market for treatment drugs for cardiovascular-renal-metabolic syndrome is expected to grow from USD 328.9 billion in 2020 to USD 468.4 billion by 2024, with a compound annual growth rate (CAGR) of 9.2%, projected to reach USD 722.5 billion by 2029 and USD 947.5 billion by 2034 [10]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 深圳信立泰藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同 意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處 長登記的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載 ...

Core Insights - The company held a roadshow in Shenzhen, attracting over 100 institutions, including IDG Capital and Anxin Fund, to discuss its strategy, R&D progress, and market positioning [1] - The company focuses on chronic disease management (CKM) with a commitment to integrity and long-termism, aiming to become a leader in the treatment of CKM syndromes [2] Financial Performance - In the first half of 2025, the company reported a revenue growth of 4.3% year-on-year, with Q2 showing a significant rebound of 12.3%, and new product revenue accounting for over 50% of total revenue [3] - The company maintains a low debt ratio and substantial cash reserves, with R&D investment consistently above 20% of revenue [3] R&D Pipeline - The company has a robust R&D pipeline in hypertension and related CKM diseases, with various drug types including oral small molecules and combination therapies, some of which are in clinical II/III phases [4] - The company is developing innovative drugs for resistant hypertension, including SAL0140 and SAL0120, and has a focus on improving patient compliance through small nucleic acid products [4][5] Market Strategy - The company has six patented drugs in the hypertension and metabolic disease sectors, with four hypertension products forming a differentiated matrix, two of which are in the medical insurance negotiation phase [6] - The company emphasizes academic promotion and patient education while exploring digital chronic disease management models for comprehensive patient lifecycle management [6] Q&A Highlights - During the Q&A session, the company addressed various market concerns, including the focus on clinical research for JK07, the independent operation of its U.S. subsidiary, and the use of AI to enhance R&D efficiency [7]

Core Viewpoint - In the first half of 2025, the company achieved operating revenue of 2.131 billion yuan (up 4.32% year-on-year) and a net profit attributable to shareholders of 365 million yuan (up 6.10% year-on-year), with a non-recurring net profit of 347 million yuan (up 3.93% year-on-year) [1][2][3] Financial Performance - The company reported total revenue of 2.131 billion yuan in the first half of 2025, a year-on-year increase of 4.32% [2][3] - The net profit attributable to shareholders was 365 million yuan, reflecting a 6.10% increase year-on-year [2][3] - The non-recurring net profit was 347 million yuan, up 3.93% year-on-year [2][3] - In Q2 2025, revenue reached 1.07 billion yuan, a 12.30% increase year-on-year, with net profit of 165 million yuan, up 14.55% [3] Product and Market Development - The company submitted 4 IND applications and received 2 clinical trial approvals in the first half of 2025, along with 2 registration certificates [2][9] - The medical device segment showed strong growth, with revenue of 182 million yuan, up 32.54% year-on-year [3][8] - The company has developed a differentiated product matrix in the hypertension field, including products like Xinlitai and Xinchao [5][6] R&D and Innovation - R&D investment accounted for 25.43% of total revenue, with significant progress in the pipeline [1][9] - The company has 31 patents authorized and submitted 136 new patent applications [2][9] - Key projects in the pipeline include SAL003 (PCSK9 monoclonal antibody) and SAL0951 (for CKD patients) [10][13] Recent Catalysts - The company is preparing for medical insurance negotiations for Xinlitai and Xinchao, which have passed preliminary reviews [13] - The successful inclusion of these products in the medical insurance directory could significantly enhance revenue contributions [13] - The company is also advancing its international clinical trials for innovative biological drugs, which may expand its market presence [13] Future Outlook - The company expects revenues of 4.496 billion yuan, 5.379 billion yuan, and 6.360 billion yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 12.05%, 19.66%, and 18.23% [14] - Net profits are projected to be 639 million yuan, 719 million yuan, and 903 million yuan for the same years, with growth rates of 6.15%, 12.62%, and 25.53% [14]